Devyser Diagnostics First Quarter 2025 Earnings: Misses Expectations

Devyser Diagnostics (STO:DVYSR) First Quarter 2025 Results

Key Financial Results

• Revenue: kr54.8m (up 8.1% from 1Q 2024).
• Net loss: kr20.5m (loss widened by 68% from 1Q 2024).
• kr1.24 loss per share (further deteriorated from kr0.75 loss in 1Q 2024).

We check all companies for important risks. See what we found for Devyser Diagnostics in our free report.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Devyser Diagnostics Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 3.8%. Earnings per share (EPS) also missed analyst estimates by 121%.

Looking ahead, revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Sweden.

Performance of the Swedish Biotechs industry.

The company's shares are up 7.1% from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We've done some analysis and you can see our take on Devyser Diagnostics' balance sheet.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.